---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-027373"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:27:44.282154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Unicycive reports FY2023 net loss of $31.4M; OLC topline data expected Q2 2024

## Summary
- FY2023 net loss $31.4M ($1.28/share) vs $18.1M ($1.20/share) in FY2022.
- Cash $9.7M at Dec 31, 2023; subsequent $50M private placement extends runway into 2026.
- Pivotal OLC trial enrollment completed; topline data expected in Q2 2024.
- UNI-494 granted FDA Orphan Drug Designation for delayed graft function; Phase 1 SAD complete, MAD ongoing.
- R&D expenses $12.9M, G&A $8.5M; licensing revenue $0.7M.

## SEC filing metadata
- accession: 0001213900-24-027373
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/0001213900-24-027373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/ea0202810-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-027373
- JSON: https://secwatch.observer/filing/0001213900-24-027373.json
- Plain text: https://secwatch.observer/filing/0001213900-24-027373.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share.
  - Period: the year ended December 31, 2023
  - Net income: Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share of common stock, compared to a net loss of $18.1 million, or $1.20 per share of common stock, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/0001213900-24-027373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.